SCHEMBL1028652

SCHEMBL1028652

CNC(=O)[C@H]1CCC[C@@H]1N1C(=O)C=CC1=O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.41
SMN1; SMN2 Q16637 4/20 0.33
KDM4E B2RXH2 2/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 1/20 0.32
TSHR P16473 4/20 0.31
RECQL P46063 2/20 0.31
HSD17B10 Q99714 1/20 0.31
MAPK1 P28482 1/20 0.31
GAA P10253 1/20 0.31
ADAM17 P78536 2/20 0.30
MMP9 P14780 1/20 0.30
MMP3 P08254 1/20 0.30
LTA4H P09960 1/20 0.30
CYP3A4 P08684 2/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1029850 0.84 KCNQ3 (0.39) SMN1; SMN2KDM4EALDH1A1TSHRRECQL
SCHEMBL1025474 0.83 TAAR1 (0.35) GRM4SMN1; SMN2KDM4EHSD17B10CYP2C9
SCHEMBL1028011 0.83 LMNA (0.36) KDM4EALDH1A1TSHRHSD17B10MAPK1
SCHEMBL1026383 0.81 SLC6A1 (0.31)
SCHEMBL1029070 0.80 GRM4 (0.47) GRM4KDM4EALDH1A1HSD17B10
SCHEMBL1025292 0.80 SLC6A2 (0.38)
SCHEMBL1074002 0.79 TAAR1 (0.44) SMN1; SMN2KDM4EALDH1A1HSD17B10GAA
SCHEMBL1025959 0.78 MAPT (0.54) SMN1; SMN2KDM4EHTTALDH1A1GAA
SCHEMBL1028998 0.78 POLB (0.45) GRM4KDM4EALDH1A1GAACYP2C9
SCHEMBL1027865 0.77 ALDH1A1 (0.35) ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479669-B1 Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography TOSOH CORP (JP) 2011-01-19 EP disclosed
US-7645889-B2 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2010-01-12 US disclosed
US-20080230482-A1 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2008-09-25 US disclosed
US-7381742-B2 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2008-06-03 US disclosed
US-20070131616-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2007-06-14 US disclosed
US-7186750-B2 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2007-03-06 US disclosed
US-20040235937-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2004-11-25 US disclosed
EP-1479669-A1 Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography Tosoh Corporation (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080230482-A1 Optically active polymaleimide derivatives and process for their production CYBA, COASY, MEP1B GRM4 1689/4885SMN1; SMN2 3147/4885KDM4E 2233/4885
US-20040235937-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them MACF1, MEP1B, CYBA GRM4 1600/4885SMN1; SMN2 2876/4885KDM4E 1805/4885
US-20070131616-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them MACF1, MEP1B, ACMSD GRM4 1649/4885SMN1; SMN2 3082/4885KDM4E 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.